279 related articles for article (PubMed ID: 10731113)
61. [Superiority of letrozole compared with tamoxifen as first line therapy of postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group].
Illiger HJ
Strahlenther Onkol; 2002 Feb; 178(2):111-3. PubMed ID: 11942036
[No Abstract] [Full Text] [Related]
62. Nonsteroidal and steroidal aromatase inhibitors in breast cancer.
Hamilton A; Volm M
Oncology (Williston Park); 2001 Aug; 15(8):965-72; discussion 972, 977-9. PubMed ID: 11548977
[TBL] [Abstract][Full Text] [Related]
63. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Morandi P; Rouzier R; Altundag K; Buzdar AU; Theriault RL; Hortobagyi G
Cancer; 2004 Oct; 101(7):1482-9. PubMed ID: 15378476
[TBL] [Abstract][Full Text] [Related]
64. Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer.
Tominaga T; Adachi I; Sasaki Y; Tabei T; Ikeda T; Takatsuka Y; Toi M; Suwa T; Ohashi Y
Ann Oncol; 2003 Jan; 14(1):62-70. PubMed ID: 12488294
[TBL] [Abstract][Full Text] [Related]
65. An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole.
Rose C; Vtoraya O; Pluzanska A; Davidson N; Gershanovich M; Thomas R; Johnson S; Caicedo JJ; Gervasio H; Manikhas G; Ben Ayed F; Burdette-Radoux S; Chaudri-Ross HA; Lang R
Eur J Cancer; 2003 Nov; 39(16):2318-27. PubMed ID: 14556923
[TBL] [Abstract][Full Text] [Related]
66. An overview of the use of non-steroidal aromatase inhibitors in the treatment of breast cancer.
Buzdar A
Eur J Cancer; 2000 Sep; 36 Suppl 4():S82-4. PubMed ID: 11056331
[TBL] [Abstract][Full Text] [Related]
67. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
Ellis MJ; Coop A; Singh B; Mauriac L; Llombert-Cussac A; Jänicke F; Miller WR; Evans DB; Dugan M; Brady C; Quebe-Fehling E; Borgs M
J Clin Oncol; 2001 Sep; 19(18):3808-16. PubMed ID: 11559718
[TBL] [Abstract][Full Text] [Related]
68. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Wardley AM
Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
[TBL] [Abstract][Full Text] [Related]
69. Pre-operative endocrine therapy for postmenopausal women: when and why?
Tondini C; Fenaroli P; Labianca R
Ann Oncol; 2001 Nov; 12(11):1505-6. PubMed ID: 11822746
[No Abstract] [Full Text] [Related]
70. Letrozole in the neoadjuvant setting: the P024 trial.
Ellis MJ; Ma C
Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):33-43. PubMed ID: 17912634
[TBL] [Abstract][Full Text] [Related]
71. Anastrozole.
Cuzick J
Drugs Today (Barc); 2005 Apr; 41(4):227-39. PubMed ID: 16034487
[TBL] [Abstract][Full Text] [Related]
72. [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
de Cremoux P; Diéras V; Poupon MF; Magdelénat H; Sigal-Zafrani B; Fourquet A; Pierga JY
Bull Cancer; 2004 Dec; 91(12):917-27. PubMed ID: 15634633
[TBL] [Abstract][Full Text] [Related]
73. Biology of aromatase inhibitors: pharmacology/endocrinology within the breast.
Miller WR
Endocr Relat Cancer; 1999 Jun; 6(2):187-95. PubMed ID: 10731108
[TBL] [Abstract][Full Text] [Related]
74. Are aromatase inhibitors superior to antiestrogens?
Howell A; Buzdar A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):237-47. PubMed ID: 15860266
[TBL] [Abstract][Full Text] [Related]
75. Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective.
Karnon J; Delea T; Barghout V
Eur J Health Econ; 2008 May; 9(2):171-83. PubMed ID: 17602251
[TBL] [Abstract][Full Text] [Related]
76. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
Dixon JM; Renshaw L; Young O; Murray J; Macaskill EJ; McHugh M; Folkerd E; Cameron DA; A'Hern RP; Dowsett M
J Clin Oncol; 2008 Apr; 26(10):1671-6. PubMed ID: 18375896
[TBL] [Abstract][Full Text] [Related]
77. Letrozole in breast cancer.
Shahab N
N Engl J Med; 2004 Feb; 350(7):727-30; author reply 727-30. PubMed ID: 14971058
[No Abstract] [Full Text] [Related]
78. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
79. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
80. Primary hormone treatment in postmenopausal women with breast cancer.
Maciá Escalante S; Pons Sanz V; Rodríguez Lescure A; Ballester Navarro I; Carrato Mena A
Clin Transl Oncol; 2006 May; 8(5):372-4. PubMed ID: 16760014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
